Publications
Adam Barak’s response to Sarah Bosely’s article printed in The Guardian, 12th April 2018
On 9 April 2018, an article by Sarah Boseley on the pricing of pharmaceuticals was printed in Britain's Guardian newspaper. Adam Barak's response can be seen here, which the Guardian printed on 12 … [Read More...] about Adam Barak’s response to Sarah Bosely’s article printed in The Guardian, 12th April 2018
Maximizing Rapid (!) Patient Access for Funded Usage of Innovative Orphan and Rare Disease Technologies
by Adam Barak MCIM Global Genes: 2017 Rare Partnering Investors Forum; September 14, 2017 Introduction With such high levels of clinical unmet need, for technologies aimed at treating rare … [Read More...] about Maximizing Rapid (!) Patient Access for Funded Usage of Innovative Orphan and Rare Disease Technologies
New UK PPRS Arrangements, 2014
In May 2014 PPi’s Managing Director Adam Barak authored an article reviewing the new UK PPRS arrangements for the web-based pharmaceutical media and debate provider, Pharmaphorum. The article hosted … [Read More...] about New UK PPRS Arrangements, 2014
Pricing policy in Europe: of cars, football, and prescription drugs
There is a tug-of-war going on between the European Commission, with laws intended to protect the free market, and business sectors hoping to claim (or retain) exclusivity. National EU governments are … [Read More...] about Pricing policy in Europe: of cars, football, and prescription drugs
Orphan drugs: pricing, reimbursement and patient access
Published in International Journal of Pharmaceutical and Healthcare Marketing Volume 5, Number 4, pp299-317 Abstract To provide a description of principal aspects of policy and practice associated … [Read More...] about Orphan drugs: pricing, reimbursement and patient access
Paying the price
Market access: International reference pricing has its limits, so is value-based pricing the answer. Excluding Ukraine, Russia, Georgia and Moldova, there are 38 separate markets in Europe where … [Read More...] about Paying the price
Caution: thresholds can sometimes be difficult to cross
Details of UK government plans for value-based pricing. Local decision-making Pharmafocus January 2011 (Volume 13, Issue 1). On December 16 the Secretary of State for Health Andrew Lansley launched … [Read More...] about Caution: thresholds can sometimes be difficult to cross
UK PPRS Overhaul
Initial views on the UK Office of Fair Trading Report. Pharmafocus March 2007 (Volume 9, Issue 3) It seems incredible that after 17 months and presumably some significant public cost, the OFT report … [Read More...] about UK PPRS Overhaul
Pharmaceutical pricing: Overview of the impact of genericisation
Published in Journal of Generic Medicines October 2003, Volume 1, Issue 1, pp21-30 Abstract Patent expiry signals a fundamental shift in the way in which drugs are marketed and purchased. The entry of … [Read More...] about Pharmaceutical pricing: Overview of the impact of genericisation
Pricing policies to handle patent loss or expiry
Published in International Journal of Medical Marketing June 2003, Volume 3, Number 3, pp245-249 Abstract Generics provide improved access to drugs for developed and developing world markets and offer … [Read More...] about Pricing policies to handle patent loss or expiry
Publications
TESTIMONIALS
“With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.”
Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.
“I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.”
Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma
“I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project.”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
“Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!”
Thomas W. MacAllister JD, PhD, Vice President of R&D and General Counsel, Remedy Pharmaceuticals
